<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04029168</url>
  </required_header>
  <id_info>
    <org_study_id>PN/25/2019</org_study_id>
    <nct_id>NCT04029168</nct_id>
  </id_info>
  <brief_title>Pelvic Floor Muscles and Success in the Surgical Treatment of Stress Urinary Incontinence and Pelvic Organ Prolapse</brief_title>
  <official_title>Pelvic Floor Muscles Efficiency as an Independent Factor of Therapeutic Success in the Surgical Treatment of Stress Urinary Incontinence and Pelvic Organ Prolapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Żelazna Medical Centre, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Żelazna Medical Centre, LLC</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is evaluation of the efficiency of pelvic floor muscles in the context
      of surgical outcomes in the treatment of stress urinary incontinence and pelvic organ
      prolapse.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pelvic Floor Distress Inventory (PFDI-20)</measure>
    <time_frame>at the baseline</time_frame>
    <description>Symptom inventory and a measure of the degree of bother and distress. The PFDI-20 includes 20 questions and 3 scales. Each of the 3 scales is scored from 0 (least distress) to 100 (greatest distress). The sum of the scores of these 3 scales serves as the overall summary score of the PFDI-20 and ranges from 0 - 300.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pelvic Floor Distress Inventory (PFDI-20)</measure>
    <time_frame>1 month post treatment</time_frame>
    <description>Symptom inventory and a measure of the degree of bother and distress. The PFDI-20 includes 20 questions and 3 scales. Each of the 3 scales is scored from 0 (least distress) to 100 (greatest distress). The sum of the scores of these 3 scales serves as the overall summary score of the PFDI-20 and ranges from 0 - 300.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pelvic Floor Distress Inventory (PFDI-20)</measure>
    <time_frame>3 months post treatment</time_frame>
    <description>Symptom inventory and a measure of the degree of bother and distress. The PFDI-20 includes 20 questions and 3 scales. Each of the 3 scales is scored from 0 (least distress) to 100 (greatest distress). The sum of the scores of these 3 scales serves as the overall summary score of the PFDI-20 and ranges from 0 - 300.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pelvic Floor Distress Inventory (PFDI-20)</measure>
    <time_frame>6 months post treatment</time_frame>
    <description>Symptom inventory and a measure of the degree of bother and distress. The PFDI-20 includes 20 questions and 3 scales. Each of the 3 scales is scored from 0 (least distress) to 100 (greatest distress). The sum of the scores of these 3 scales serves as the overall summary score of the PFDI-20 and ranges from 0 - 300.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pelvic Floor Distress Inventory (PFDI-20)</measure>
    <time_frame>Change from the baseline till 1 month post treatment</time_frame>
    <description>Symptom inventory and a measure of the degree of bother and distress. The PFDI-20 includes 20 questions and 3 scales. Each of the 3 scales is scored from 0 (least distress) to 100 (greatest distress). The sum of the scores of these 3 scales serves as the overall summary score of the PFDI-20 and ranges from 0 - 300.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pelvic Floor Distress Inventory (PFDI-20)</measure>
    <time_frame>change from the baseline till 3 months post treatment</time_frame>
    <description>Symptom inventory and a measure of the degree of bother and distress. The PFDI-20 includes 20 questions and 3 scales. Each of the 3 scales is scored from 0 (least distress) to 100 (greatest distress). The sum of the scores of these 3 scales serves as the overall summary score of the PFDI-20 and ranges from 0 - 300.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pelvic Floor Distress Inventory (PFDI-20)</measure>
    <time_frame>change from the baseline till 6 months post treatment</time_frame>
    <description>Symptom inventory and a measure of the degree of bother and distress. The PFDI-20 includes 20 questions and 3 scales. Each of the 3 scales is scored from 0 (least distress) to 100 (greatest distress). The sum of the scores of these 3 scales serves as the overall summary score of the PFDI-20 and ranges from 0 - 300.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analogue Scale</measure>
    <time_frame>at the baseline</time_frame>
    <description>Distress assessment range 0-10, higher numbers represent better outcomes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analogue Scale</measure>
    <time_frame>1 month post treatment</time_frame>
    <description>Distress assessment range 0-10, higher numbers represent better outcomes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analogue Scale</measure>
    <time_frame>3 month post treatment</time_frame>
    <description>Distress assessment range 0-10, higher numbers represent better outcomes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analogue Scale</measure>
    <time_frame>6 months post treatment</time_frame>
    <description>Distress assessment range 0-10, higher numbers represent better outcomes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analogue Scale</measure>
    <time_frame>change from the baseline till 1 months post treatment</time_frame>
    <description>Distress assessment range 0-10, higher numbers represent better outcomes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analogue Scale</measure>
    <time_frame>change from the baseline till 3 months post treatment</time_frame>
    <description>Distress assessment range 0-10, higher numbers represent better outcomes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analogue Scale</measure>
    <time_frame>change from the baseline till 6 months post treatment</time_frame>
    <description>Distress assessment range 0-10, higher numbers represent better outcomes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PELVIC FLOOR IMPACT QUESTIONNAIRE SHORT FORM (PFIQ-7)</measure>
    <time_frame>at the baseline</time_frame>
    <description>Assessment of life impact in women with pelvic floor disorders, range 0-300, higher numbers indicate greater impact</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PELVIC FLOOR IMPACT QUESTIONNAIRE SHORT FORM (PFIQ-7)</measure>
    <time_frame>1 month post treatment</time_frame>
    <description>Assessment of life impact in women with pelvic floor disorders, range 0-300, higher numbers indicate greater impact</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PELVIC FLOOR IMPACT QUESTIONNAIRE SHORT FORM (PFIQ-7)</measure>
    <time_frame>3 month post treatment</time_frame>
    <description>Assessment of life impact in women with pelvic floor disorders, range 0-300, higher numbers indicate greater impact</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PELVIC FLOOR IMPACT QUESTIONNAIRE SHORT FORM (PFIQ-7)</measure>
    <time_frame>6 months post treatment</time_frame>
    <description>Assessment of life impact in women with pelvic floor disorders, range 0-300, higher numbers indicate greater impact</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PELVIC FLOOR IMPACT QUESTIONNAIRE SHORT FORM (PFIQ-7)</measure>
    <time_frame>change from the baseline till 1 month post treatment</time_frame>
    <description>Assessment of life impact in women with pelvic floor disorders, range 0-300, higher numbers indicate greater impact</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PELVIC FLOOR IMPACT QUESTIONNAIRE SHORT FORM (PFIQ-7)</measure>
    <time_frame>change from the baseline till 3 months post treatment</time_frame>
    <description>Assessment of life impact in women with pelvic floor disorders, range 0-300, higher numbers indicate greater impact</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PELVIC FLOOR IMPACT QUESTIONNAIRE SHORT FORM (PFIQ-7)</measure>
    <time_frame>change from the baseline till 6 months post treatment</time_frame>
    <description>Assessment of life impact in women with pelvic floor disorders, range 0-300, higher numbers indicate greater impact</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incontinence impact Questionnaire-Short Form (IIQ-7 SF)</measure>
    <time_frame>at the baseline</time_frame>
    <description>To measure the impact of urinary incontinence on activities, roles and emotional states</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incontinence impact Questionnaire-Short Form (IIQ-7 SF)</measure>
    <time_frame>at 1 month post treatment</time_frame>
    <description>To measure the impact of urinary incontinence on activities, roles and emotional states</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incontinence impact Questionnaire-Short Form (IIQ-7 SF)</measure>
    <time_frame>3 months post treatment</time_frame>
    <description>To measure the impact of urinary incontinence on activities, roles and emotional states</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incontinence impact Questionnaire-Short Form (IIQ-7 SF)</measure>
    <time_frame>6 months post treatment</time_frame>
    <description>To measure the impact of urinary incontinence on activities, roles and emotional states</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incontinence impact Questionnaire-Short Form (IIQ-7 SF)</measure>
    <time_frame>change from the baseline till 1 month post treatment</time_frame>
    <description>To measure the impact of urinary incontinence on activities, roles and emotional states</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incontinence impact Questionnaire-Short Form (IIQ-7 SF)</measure>
    <time_frame>change from the baseline till 3 months post treatment</time_frame>
    <description>To measure the impact of urinary incontinence on activities, roles and emotional states</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incontinence impact Questionnaire-Short Form (IIQ-7 SF)</measure>
    <time_frame>change from the baseline till 6 months post treatment</time_frame>
    <description>To measure the impact of urinary incontinence on activities, roles and emotional states</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pelvic floor organ prolapse quantification (POP-Q)</measure>
    <time_frame>at baseline</time_frame>
    <description>Quantification of pelvic organ prolapse, range 0-4, higher indicate worse outcomes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pelvic floor organ prolapse quantification (POP-Q)</measure>
    <time_frame>at 1 month post treatment</time_frame>
    <description>Quantification of pelvic organ prolapse, range 0-4, higher indicate worse outcomes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pelvic floor organ prolapse quantification (POP-Q)</measure>
    <time_frame>3 months post treatment</time_frame>
    <description>Quantification of pelvic organ prolapse, range 0-4, higher indicate worse outcomes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pelvic floor organ prolapse quantification (POP-Q)</measure>
    <time_frame>6 months post treatment</time_frame>
    <description>Quantification of pelvic organ prolapse, range 0-4, higher indicate worse outcomes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pelvic floor organ prolapse quantification (POP-Q)</measure>
    <time_frame>change from the baseline till 1 month post treatment</time_frame>
    <description>Quantification of pelvic organ prolapse, range 0-4, higher indicate worse outcomes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pelvic floor organ prolapse quantification (POP-Q)</measure>
    <time_frame>change from the baseline till 3 month post treatment</time_frame>
    <description>Quantification of pelvic organ prolapse, range 0-4, higher indicate worse outcomes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pelvic floor organ prolapse quantification (POP-Q)</measure>
    <time_frame>change from the baseline till 6 month post treatment</time_frame>
    <description>Quantification of pelvic organ prolapse, range 0-4, higher indicate worse outcomes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Marshall-Bonney test</measure>
    <time_frame>at the baseline</time_frame>
    <description>Assessment of stress urinary incontinence, test can be negative or positive, positive test indicates incontinence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Marshall-Bonney test</measure>
    <time_frame>at 1 month post treatment</time_frame>
    <description>Assessment of stress urinary incontinence, test can be negative or positive, positive test indicates incontinence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Marshall-Bonney test</measure>
    <time_frame>3 months post treatment</time_frame>
    <description>Assessment of stress urinary incontinence, test can be negative or positive, positive test indicates incontinence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Marshall-Bonney test</measure>
    <time_frame>6 months post treatment</time_frame>
    <description>Assessment of stress urinary incontinence, test can be negative or positive, positive test indicates incontinence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Marshall-Bonney test</measure>
    <time_frame>change from the baseline till 1 month post treatment</time_frame>
    <description>Assessment of stress urinary incontinence, test can be negative or positive, positive test indicates incontinence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Marshall-Bonney test</measure>
    <time_frame>change from the baseline till 3 months post treatment</time_frame>
    <description>Assessment of stress urinary incontinence, test can be negative or positive, positive test indicates incontinence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Marshall-Bonney test</measure>
    <time_frame>change from the baseline till 6 months post treatment</time_frame>
    <description>Assessment of stress urinary incontinence, test can be negative or positive, positive test indicates incontinence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pelvic Floor Muscle Strength</measure>
    <time_frame>assessment at the baseline</time_frame>
    <description>Assessment of Pelvic Floor Muscle Strength measured as increase of intravaginal pressure by perineometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pelvic Floor Muscle Strength</measure>
    <time_frame>assessment 1 month post treatment</time_frame>
    <description>Assessment of Pelvic Floor Muscle Strength measured as increase of intravaginal pressure by perineometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pelvic Floor Muscle Strength</measure>
    <time_frame>assessment 3 months post treatment</time_frame>
    <description>Assessment of Pelvic Floor Muscle Strength measured as increase of intravaginal pressure by perineometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pelvic Floor Muscle Strength</measure>
    <time_frame>assessment 6 months post treatment</time_frame>
    <description>Assessment of Pelvic Floor Muscle Strength measured as increase of intravaginal pressure by perineometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pelvic Floor Muscle Strength</measure>
    <time_frame>assessment of change from the baseline till 1 mont post treatment</time_frame>
    <description>Assessment of Pelvic Floor Muscle Strength measured as increase of intravaginal pressure by perineometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pelvic Floor Muscle Strength</measure>
    <time_frame>assessment of change from the baseline till 3 monts post treatment</time_frame>
    <description>Assessment of Pelvic Floor Muscle Strength measured as increase of intravaginal pressure by perineometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pelvic Floor Muscle Strength</measure>
    <time_frame>assessment of change from the baseline till 6 monts post treatment</time_frame>
    <description>Assessment of Pelvic Floor Muscle Strength measured as increase of intravaginal pressure by perineometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pelvic Floor Muscle Endurance</measure>
    <time_frame>assessment at the baseline</time_frame>
    <description>Assessment of pelvic floor endurance measured by area under the curve by perineometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pelvic Floor Muscle Endurance</measure>
    <time_frame>assessment 1 month post treatment</time_frame>
    <description>Assessment of pelvic floor endurance measured by area under the curve by perineometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pelvic Floor Muscle Endurance</measure>
    <time_frame>assessment 3 months post treatment</time_frame>
    <description>Assessment of pelvic floor endurance measured by area under the curve by perineometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pelvic Floor Muscle Endurance</measure>
    <time_frame>assessment 6 months post treatment</time_frame>
    <description>Assessment of pelvic floor endurance measured by area under the curve by perineometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pelvic Floor Muscle Endurance</measure>
    <time_frame>assessment of change from the baseline till 1 month post treatment</time_frame>
    <description>Assessment of pelvic floor endurance measured by area under the curve by perineometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pelvic Floor Muscle Endurance</measure>
    <time_frame>assessment of change from the baseline till 3 months post treatment</time_frame>
    <description>Assessment of pelvic floor endurance measured by area under the curve by perineometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pelvic Floor Muscle Endurance</measure>
    <time_frame>assessment of change from the baseline till 6 months post treatment</time_frame>
    <description>Assessment of pelvic floor endurance measured by area under the curve by perineometry</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Stress Urinary Incontinence</condition>
  <condition>Pelvic Organ Prolapse</condition>
  <condition>Pelvic Floor Disorders</condition>
  <arm_group>
    <arm_group_label>weak pelvic floor muscles</arm_group_label>
    <description>The group will consist of females with pelvic floor strength lower or equal to 26.5 measured by perineometry and/or females with lack of ability to sustain stable pelvic floor contraction at submaximal level (80% of maximal voluntary contraction) for 5 seconds.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>strong pelvic floor muscles</arm_group_label>
    <description>The group will consist of females with pelvic floor strength over 26.5 measured by perineometry and/or females with ability to sustain stable pelvic floor contraction at submaximal level (80% of maximal voluntary contraction) for 5 seconds.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>pelvic floor surgery</intervention_name>
    <description>midurethral slings and pelvic organ prolapse surgical procedures</description>
    <arm_group_label>strong pelvic floor muscles</arm_group_label>
    <arm_group_label>weak pelvic floor muscles</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women with stress urinary incontinence and pelvic organ prolapse
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  premenopausal and postmenopausal women

          -  stress urinary incontinence

          -  pelvic organ prolapse

        Exclusion Criteria:

        - previous surgical interventions due to stress urinary incontinence or pelvic organ
        prolapse
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>participant eligibility is based on self-representation of gender identity.</gender_description>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Dorota Sys, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre of Postgraduate Medical Education</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacek Szymański, MD, PhD</last_name>
    <phone>+48601243792</phone>
    <email>jkszymanski2@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centrum Medyczne &quot;ŻELAZNA&quot;</name>
      <address>
        <city>Warsaw</city>
        <zip>01-004</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacek Szymański, MD, PhD</last_name>
      <email>jkszymanski2@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jacek Szymański, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 9, 2019</study_first_submitted>
  <study_first_submitted_qc>July 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2019</study_first_posted>
  <last_update_submitted>January 16, 2020</last_update_submitted>
  <last_update_submitted_qc>January 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
    <mesh_term>Pelvic Floor Disorders</mesh_term>
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Pelvic Organ Prolapse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

